BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-800. [PMID: 25773268 DOI: 10.1056/NEJMoa1500857] [Cited by in Crossref: 1093] [Cited by in F6Publishing: 215] [Article Influence: 182.2] [Reference Citation Analysis]
Number Citing Articles
1 Lau ES, Braunwald E, Morrow DA, Giugliano RP, Antman EM, Gibson CM, Scirica BM, Bohula EA, Wiviott SD, Bhatt DL, Bonaca MP, Cannon CP, Im K, Guo J, Sabatine MS, O'Donoghue ML. Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation 2021;143:685-95. [PMID: 33587654 DOI: 10.1161/CIRCULATIONAHA.120.052339] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, Branch KRH, Probstfield J, Bosch J, Shestakovska O, Szarek M, Maggioni AP, Widimský P, Avezum A, Diaz R, Lewis BS, Berkowitz SD, Fox KAA, Ryden L, Yusuf S; COMPASS Steering Committee and Investigators. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. Circulation 2020;141:1841-54. [PMID: 32223318 DOI: 10.1161/CIRCULATIONAHA.120.046448] [Cited by in Crossref: 45] [Cited by in F6Publishing: 10] [Article Influence: 45.0] [Reference Citation Analysis]
3 Abtan J, Bhatt DL, Elbez Y, Sorbets E, Eagle K, Reid CM, Baumgartner I, Wu D, Hanson ME, Hannachi H, Singhal PK, Steg PG, Ducrocq G; REACH Registry Investigators. Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry. Clin Cardiol 2017;40:710-8. [PMID: 28520087 DOI: 10.1002/clc.22721] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
4 Angiolillo DJ, Bhatt DL, Steg PG, Stone GW, White HD, Gibson CM, Hamm CW, Price MJ, Prats J, Liu T, Mahaffey KW, Harrington RA. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. J Thromb Thrombolysis 2015;40:317-22. [PMID: 26024789 DOI: 10.1007/s11239-015-1233-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
5 Bellettini E, De Luca L. Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke. J Clin Med 2021;10:1923. [PMID: 33946834 DOI: 10.3390/jcm10091923] [Reference Citation Analysis]
6 Su Y, Cheng X, Dong Q. Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications. CNS Neurosci Ther 2015;21:870-6. [PMID: 26122554 DOI: 10.1111/cns.12419] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Soden PA, Zettervall SL, Ultee KH, Landon BE, O'Malley AJ, Goodney PP, DeMartino RR, Arya S, Schermerhorn ML; Society for Vascular Surgery Vascular Quality Initiative. Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization. J Vasc Surg 2016;64:1633-1644.e1. [PMID: 27575814 DOI: 10.1016/j.jvs.2016.05.098] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 4.4] [Reference Citation Analysis]
8 Roth C, Schneider M, Dalos D, Gangl C, Toth C, Goliasch G, Berger R. High N-Terminal proB-Type Natriuretic Peptide Indicates Elevated Risk of Death after Percutaneous Coronary Intervention Compared to Coronary Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. J Clin Med 2019;8:E898. [PMID: 31234593 DOI: 10.3390/jcm8060898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
9 Cao D, Dangas G, Mehran R. Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction: Bleeding Avoidance First and Foremost. J Am Heart Assoc 2021;10:e019889. [PMID: 33559475 DOI: 10.1161/JAHA.120.019889] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Marston NA, Patel PN, Kamanu FK, Nordio F, Melloni GM, Roselli C, Gurmu Y, Weng LC, Bonaca MP, Giugliano RP, Scirica BM, O'Donoghue ML, Cannon CP, Anderson CD, Bhatt DL, Gabriel Steg P, Cohen M, Storey RF, Sever P, Keech AC, Raz I, Mosenzon O, Antman EM, Braunwald E, Ellinor PT, Lubitz SA, Sabatine MS, Ruff CT. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation 2021;143:470-8. [PMID: 33185476 DOI: 10.1161/CIRCULATIONAHA.120.051927] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
11 Park S, Choi YJ, Kang JE, Kim MG, Jung Geum M, Kim SD, Rhie SJ. P2Y12 Antiplatelet Choice for Patients with Chronic Kidney Disease and Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. J Pers Med 2021;11:222. [PMID: 33801161 DOI: 10.3390/jpm11030222] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovasc Disord 2017;17:53. [PMID: 28173750 DOI: 10.1186/s12872-017-0482-9] [Cited by in Crossref: 75] [Cited by in F6Publishing: 56] [Article Influence: 18.8] [Reference Citation Analysis]
13 Kupka D, Sibbing D. De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention. Korean Circ J 2018;48:863-72. [PMID: 30238704 DOI: 10.4070/kcj.2018.0255] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
14 Kawamura Y, Tamura N, Goto S, Goto S. Computer Simulation of Platelet Adhesion around Stent Struts in the Presence and Absence of Tissue Defects around Them. J Interv Cardiol 2021;2021:8880988. [PMID: 33628146 DOI: 10.1155/2021/8880988] [Reference Citation Analysis]
15 Lordkipanidzé M, Marquis-Gravel G, Tanguay JF, Mehta SR, So DYF. Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada. CJC Open 2021;3:814-21. [PMID: 34169260 DOI: 10.1016/j.cjco.2020.11.021] [Reference Citation Analysis]
16 Sanchez F, Boasi V, Vercellino M, Tacchi C, Cannarile P, Pingelli N, Perri D, Gomez L, Cattunar S, Mascelli G. Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a "real world" STEMI population: results from the Italian "CARDIO-STEMI SANREMO" registry. BMC Cardiovasc Disord 2021;21:144. [PMID: 33736607 DOI: 10.1186/s12872-020-01780-y] [Reference Citation Analysis]
17 Lindholm D, Hagström E, James SK, Becker RC, Cannon CP, Himmelmann A, Katus HA, Maurer G, López-Sendón JL, Steg PG, Storey RF, Siegbahn A, Wallentin L. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. J Am Heart Assoc 2017;6:e005580. [PMID: 28411246 DOI: 10.1161/JAHA.117.005580] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
18 Ziegler M, Wang X, Peter K. Platelets in cardiac ischaemia/reperfusion injury: a promising therapeutic target. Cardiovasc Res 2019;115:1178-88. [PMID: 30906948 DOI: 10.1093/cvr/cvz070] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 31.0] [Reference Citation Analysis]
19 Stone GW, Hochman JS, Williams DO, Boden WE, Ferguson TB, Harrington RA, Maron DJ. Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise. J Am Coll Cardiol. 2016;67:81-99. [PMID: 26616030 DOI: 10.1016/j.jacc.2015.09.056] [Cited by in Crossref: 65] [Cited by in F6Publishing: 42] [Article Influence: 10.8] [Reference Citation Analysis]
20 Chaturvedula S, Diver D, Vashist A. Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. J Clin Med 2018;7:E74. [PMID: 29642547 DOI: 10.3390/jcm7040074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
21 Ostrowska M, Kubica J, Adamski P, Kubica A, Eyileten C, Postula M, Toma A, Hengstenberg C, Siller-Matula JM. Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. Front Cardiovasc Med 2019;6:176. [PMID: 31850373 DOI: 10.3389/fcvm.2019.00176] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
22 Eisinger F, Patzelt J, Langer HF. The Platelet Response to Tissue Injury. Front Med (Lausanne) 2018;5:317. [PMID: 30483508 DOI: 10.3389/fmed.2018.00317] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 10.3] [Reference Citation Analysis]
23 Kim DY, Cho SW, Park KT, Ahn JH, Park TK, Jang YH, Choi KH, Lee JM, Yang JH, Song YB, Choi JH, Choi SH, Gwon HC, Lee SH, Hahn JY. Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients. J Korean Med Sci 2021;36:e106. [PMID: 33904262 DOI: 10.3346/jkms.2021.36.e106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Bradley SM, Hess GP, Stewart P, Armstrong EJ, Farmer SA, Wasfy JH, Valle JA, Sandhu A, Maddox TM. Implications of the PEGASUS-TIMI 54 trial for US clinical practice. Open Heart 2017;4:e000580. [PMID: 28674626 DOI: 10.1136/openhrt-2016-000580] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Cordonnier C, Lemesle G, Casolla B, Bic M, Caparros F, Lamblin N, Bauters C. Incidence and determinants of cerebrovascular events in outpatients with stable coronary artery disease. Eur Stroke J 2018;3:272-80. [PMID: 31008358 DOI: 10.1177/2396987318772684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, Wiviott SD, Cohen DJ, Massaro JM, D'Agostino RB Sr, Braunwald E, Kereiakes DJ; DAPT Study Investigators. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J 2016;37:378-85. [PMID: 26586780 DOI: 10.1093/eurheartj/ehv614] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
27 Kubica J, Adamski P, Niezgoda P, Kubica A, Podhajski P, Barańska M, Umińska JM, Pietrzykowski Ł, Ostrowska M, Siller-Matula JM, Badarienė J, Bartuś S, Budaj A, Dobrzycki S, Fidor Ł, Gąsior M, Gessek J, Gierlotka M, Gil R, Gorący J, Grzelakowski P, Hajdukiewicz T, Jaguszewski M, Janion M, Kasprzak J, Kern A, Klecha A, Kleinrok A, Kochman W, Krakowiak B, Legutko J, Lesiak M, Nosal M, Piotrowski G, Przybylski A, Roleder T, Skonieczny G, Sobieszek G, Tycińska A, Wojciechowski D, Wojakowski W, Wójcik J, Zielińska M, Żurakowski A, Specchia G, Gorog DA, Navarese EP. A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiol J 2021;28:607-14. [PMID: 34096012 DOI: 10.5603/CJ.a2021.0056] [Reference Citation Analysis]
28 Tersalvi G, Biasco L, Cioffi GM, Pedrazzini G. Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective. J Clin Med 2020;9:E2064. [PMID: 32630233 DOI: 10.3390/jcm9072064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
29 Kreutz RP, Schmeisser G, Maatman B, Schaffter A, Sinha A, von der Lohe E, Breall JA. Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention. Thromb Haemost 2017;117:426-8. [PMID: 27808346 DOI: 10.1160/TH16-10-0496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
30 Capodanno D, Alberts M, Angiolillo DJ. Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. Nat Rev Cardiol 2016;13:609-22. [PMID: 27489191 DOI: 10.1038/nrcardio.2016.111] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
31 Degrauwe S, Pilgrim T, Aminian A, Noble S, Meier P, Iglesias JF. Dual antiplatelet therapy for secondary prevention of coronary artery disease. Open Heart 2017;4:e000651. [PMID: 29081979 DOI: 10.1136/openhrt-2017-000651] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
32 Costa F, Ariotti S, Valgimigli M, Kolh P, Windecker S; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization : Fifty Years of Revascularization: Where Are We and Where Are We Heading? J Cardiovasc Transl Res 2015;8:211-20. [PMID: 25986910 DOI: 10.1007/s12265-015-9632-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
33 Miyazaki Y, Suwannasom P, Sotomi Y, Abdelghani M, Tummala K, Katagiri Y, Asano T, Tenekecioglu E, Zeng Y, Cavalcante R, Collet C, Onuma Y, Serruys PW. Single or dual antiplatelet therapy after PCI. Nat Rev Cardiol 2017;14:294-303. [PMID: 28181585 DOI: 10.1038/nrcardio.2017.12] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
34 Li Y, Jing Q, Wang B, Wang X, Li J, Qiao S, Chen S, Angiolillo DJ, Han Y. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. Am Heart J 2020;228:1-7. [PMID: 32739652 DOI: 10.1016/j.ahj.2020.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Olie RH, van der Meijden PEJ, Ten Cate H. The coagulation system in atherothrombosis: Implications for new therapeutic strategies. Res Pract Thromb Haemost 2018;2:188-98. [PMID: 30046721 DOI: 10.1002/rth2.12080] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 6.7] [Reference Citation Analysis]
36 Serrano CV Jr, Soeiro AM, Leal TCAT, Godoy LC, Biselli B, Hata LA, Martins EB, Abud-Manta ICK, Tavares CAM, Cardozo FAM, Oliveira MT Jr. Statement on Antiplatelet Agents and Anticoagulants in Cardiology - 2019. Arq Bras Cardiol 2019;113:111-34. [PMID: 31411300 DOI: 10.5935/abc.20190128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Angheloiu GO, Gugiu GB, Ruse C, Pandey R, Dasari RR, Whatling C. Ticagrelor Removal From Human Blood. JACC Basic Transl Sci 2017;2:135-45. [PMID: 30167561 DOI: 10.1016/j.jacbts.2017.01.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
38 Zhao Q, Zhu Y, Xu Z, Cheng Z, Mei J, Chen X, Wang X. Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial. JAMA 2018;319:1677-86. [PMID: 29710164 DOI: 10.1001/jama.2018.3197] [Cited by in Crossref: 76] [Cited by in F6Publishing: 53] [Article Influence: 25.3] [Reference Citation Analysis]
39 Toda Kato E, Goto S. The TIMI Study Group's Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease. J Atheroscler Thromb 2021;28:563-72. [PMID: 33853997 DOI: 10.5551/jat.RV17049] [Reference Citation Analysis]
40 Patti G, Cavallari I, Antonucci E, Calabrò P, Cirillo P, Gresele P, Palareti G, Pengo V, Pignatelli P, Ricottini E, Marcucci R. Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. PLoS One 2017;12:e0186961. [PMID: 29059255 DOI: 10.1371/journal.pone.0186961] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
41 Xiang Z, Yang J, Yang J, Zhang J, Fan Z, Yang C, Di L, Ma C, Wu J, Huang Y. Efficacy and safety of colchicine for secondary prevention of coronary heart disease: a systematic review and meta-analysis. Intern Emerg Med 2021;16:487-96. [PMID: 33400158 DOI: 10.1007/s11739-020-02606-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
42 Tan JW, Chew DP, Abdul Kader MAS, Ako J, Bahl VK, Chan M, Park KW, Chandra P, Hsieh IC, Huan DQ, Johar S, Juzar DA, Kim BK, Lee CW, Lee MK, Li YH, Almahmeed W, Sison EO, Tan D, Wang YC, Yeh SJ, Montalescot G. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region. Eur Cardiol 2021;16:e02. [PMID: 33708263 DOI: 10.15420/ecr.2020.40] [Reference Citation Analysis]
43 Bagai A, Lu D, Lucas J, Goyal A, Herzog CA, Wang TY, Goodman SG, Roe MT. Temporal Trends in Utilization of Cardiac Therapies and Outcomes for Myocardial Infarction by Degree of Chronic Kidney Disease: A Report From the NCDR Chest Pain-MI Registry. J Am Heart Assoc 2018;7:e010394. [PMID: 30514137 DOI: 10.1161/JAHA.118.010394] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
44 Pocock SJ, Brieger D, Gregson J, Chen JY, Cohen MG, Goodman SG, Granger CB, Grieve R, Nicolau JC, Simon T, Westermann D, Yasuda S, Hedman K, Rennie KL, Sundell KA; TIGRIS Study Investigators. Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. Clin Cardiol 2020;43:24-32. [PMID: 31713893 DOI: 10.1002/clc.23283] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
45 Majithia A, Bhatt DL. Novel Antiplatelet Therapies for Atherothrombotic Diseases. Arterioscler Thromb Vasc Biol 2019;39:546-57. [PMID: 30760019 DOI: 10.1161/ATVBAHA.118.310955] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 20.0] [Reference Citation Analysis]
46 Reid C, Alturki A, Yan A, So D, Ko D, Tanguay JF, Bessissow A, Mehta S, Goodman S, Huynh T. Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy. CJC Open 2020;2:118-28. [PMID: 32462125 DOI: 10.1016/j.cjco.2020.02.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Gao C, Tomaniak M, Takahashi K, Kawashima H, Wang R, Hara H, Ono M, Montalescot G, Garg S, Haude M, Slagboom T, Vranckx P, Valgimigli M, Windecker S, van Geuns RJ, Hamm C, Steg PG, Onuma Y, Angiolillo DJ, Serruys PW. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovasc Diabetol 2020;19:179. [PMID: 33066794 DOI: 10.1186/s12933-020-01153-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Pasea L, Chung SC, Pujades-Rodriguez M, Moayyeri A, Denaxas S, Fox KAA, Wallentin L, Pocock SJ, Timmis A, Banerjee A, Patel R, Hemingway H. Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. Eur Heart J 2017;38:1048-55. [PMID: 28329300 DOI: 10.1093/eurheartj/ehw683] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
49 Rossello X, Bueno H, Pocock SJ, Van de Werf F, Danchin N, Annemans L, Medina J, Zeymer U. Predictors of all-cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: Results from the EPICOR registry. Clin Cardiol 2019;42:111-9. [PMID: 30443916 DOI: 10.1002/clc.23116] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
50 Darmon A, Ducrocq G, Jasilek A, Feldman L, Sorbets E, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG. Use of risk scores to identify lower and higher risk subsets among COMPASS-eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry. Clin Cardiol 2021;44:58-65. [PMID: 33274779 DOI: 10.1002/clc.23505] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Zhu H, Xu X, Fang X, Ying F, Song L, Gao B, Tong G, Zhou L, Chen T, Huang J. Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-analysis of Randomized Controlled Trials. J Am Heart Assoc 2021;10:e019184. [PMID: 33682435 DOI: 10.1161/JAHA.120.019184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Radaideh Q, Shammas NW, Daher GE, Rachwan RJ. Medical and Revascularization Management of Stable Ischemic Heart Disease: An Overview. Int J Angiol 2021;30:83-90. [PMID: 34025099 DOI: 10.1055/s-0040-1722739] [Reference Citation Analysis]
53 Fong LCW, Ford TJ, da Costa BR, Jüni P, Berry C. Bias and Loss to Follow-Up in Cardiovascular Randomized Trials: A Systematic Review. J Am Heart Assoc 2020;9:e015361. [PMID: 32646264 DOI: 10.1161/JAHA.119.015361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Horne BD, Muhlestein JB, Bhandary D, Hoetzer GL, Khan ND, Bair TL, Lappé DL. Clinically feasible stratification of 1-year to 3-year post-myocardial infarction risk. Open Heart 2018;5:e000723. [PMID: 29531761 DOI: 10.1136/openhrt-2017-000723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
55 Kanter J, Abboud MR, Kaya B, Nduba V, Amilon C, Gottfridsson C, Rensfeldt M, Leonsson-Zachrisson M; HESTIA2 study investigators. Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study. Br J Haematol 2019;184:269-78. [PMID: 30443999 DOI: 10.1111/bjh.15646] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
56 Kytö V, Prami T, Khanfir H, Hasvold P, Reissell E, Airaksinen J. Usage of PCI and long-term cardiovascular risk in post-myocardial infarction patients: a nationwide registry cohort study from Finland. BMC Cardiovasc Disord 2019;19:123. [PMID: 31117956 DOI: 10.1186/s12872-019-1101-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
57 Yeh JS, Hsu CY, Huang CY, Chen WT, Hsieh YC, Chien LN. The effect of de-escalation of P2Y12 receptor inhibitor therapy after acute myocardial infarction in patients undergoing percutaneous coronary intervention: A nationwide cohort study. PLoS One 2021;16:e0246029. [PMID: 33493236 DOI: 10.1371/journal.pone.0246029] [Reference Citation Analysis]
58 Goto S, Goto S. Is the answer to clinical questions provided by Bayesian network meta-analysis? Regarding the optimal duration of DAPT and the best subsequent SAPT. Eur Heart J Cardiovasc Pharmacother 2021;7:216-7. [PMID: 32424398 DOI: 10.1093/ehjcvp/pvaa032] [Reference Citation Analysis]
59 Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, Zurakowski A, Schotborgh CE, Hoorntje JCA, Eek CH, Cook S, Togni M, Meuwissen M, van Royen N, van Vliet R, Wedel H, Delewi R, Zijlstra F. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ 2018;363:k3793. [PMID: 30279197 DOI: 10.1136/bmj.k3793] [Cited by in Crossref: 67] [Cited by in F6Publishing: 45] [Article Influence: 22.3] [Reference Citation Analysis]
60 Rivas Rios JR, Franchi F, Rollini F, Angiolillo DJ. Diabetes and antiplatelet therapy: from bench to bedside. Cardiovasc Diagn Ther 2018;8:594-609. [PMID: 30498684 DOI: 10.21037/cdt.2018.05.09] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
61 Mansour A, Bachelot-Loza C, Nesseler N, Gaussem P, Gouin-Thibault I. P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation. Int J Mol Sci 2020;21:E1391. [PMID: 32092903 DOI: 10.3390/ijms21041391] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 20.0] [Reference Citation Analysis]
62 Åström A, Söderström L, Mooe T. Risk of Ischemic Stroke After Acute Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery. Sci Rep 2020;10:3831. [PMID: 32123285 DOI: 10.1038/s41598-020-60854-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Westermann D, Goodman SG, Nicolau JC, Requena G, Maguire A, Chen JY, Granger CB, Grieve R, Pocock SJ, Blankenberg S, Vega AM, Yasuda S, Simon T, Brieger D; TIGRIS Study Investigators. Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study. Clin Cardiol 2017;40:1197-204. [PMID: 29247524 DOI: 10.1002/clc.22837] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
64 Lavi S, Alemayehu M, Puka K, Wall S, Lavi R. Association Between Administration of Ticagrelor and Microvascular Endothelial Function. JAMA Cardiol 2017;2:1042-4. [PMID: 28746721 DOI: 10.1001/jamacardio.2017.2378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
65 Pelletier-Galarneau M, Hunter CRRN, Ascah KJ, Beanlands RSB, Dwivedi G, deKemp RA, Chow BJW, Ruddy TD. Randomized Trial Comparing the Effects of Ticagrelor Versus Clopidogrel on Myocardial Perfusion in Patients With Coronary Artery Disease. J Am Heart Assoc 2017;6:e005894. [PMID: 28465300 DOI: 10.1161/JAHA.117.005894] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
66 Lindholm D, Sarno G, Erlinge D, Svennblad B, Hasvold LP, Janzon M, Jernberg T, James SK. Combined association of key risk factors on ischaemic outcomes and bleeding in patients with myocardial infarction. Heart 2019;105:1175-81. [PMID: 31055499 DOI: 10.1136/heartjnl-2018-314590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Akkaif MA, Ng ML, Sk Abdul Kader MA, Daud NAA, Sha'aban A, Ibrahim B. A review of the effects of ticagrelor on adenosine concentration and its clinical significance. Pharmacol Rep 2021. [PMID: 34283374 DOI: 10.1007/s43440-021-00309-0] [Reference Citation Analysis]
68 Ismail N, Jordan KP, Rao S, Kinnaird T, Potts J, Kadam UT, Mamas MA. Incidence and prognostic impact of post discharge bleeding post acute coronary syndrome within an outpatient setting: a systematic review. BMJ Open 2019;9:e023337. [PMID: 30787079 DOI: 10.1136/bmjopen-2018-023337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
69 Soehnlein O. [Atherothrombosis : Novel therapeutic strategies]. Herz 2018;43:103-8. [PMID: 29236146 DOI: 10.1007/s00059-017-4659-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Krackhardt F, Waliszewski M, Rischner J, Piot C, Pansieri M, Ruiz-Poveda FL, Boxberger M, Noutsias M, Ríos XF, Kherad B. Nine-month clinical outcomes in patients with diabetes treated with polymer-free sirolimus-eluting stents and 6‑month vs. 12‑month dual-antiplatelet therapy (DAPT). Herz 2019;44:433-9. [PMID: 29356832 DOI: 10.1007/s00059-017-4675-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Biscaglia S, Tonet E, Pavasini R, Serenelli M, Bugani G, Cimaglia P, Gallo F, Spitaleri G, Del Franco A, Aquila G, Vieceli Dalla Sega F, Tebaldi M, Tumscitz C, Ferrari R, Campo G. A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial. PLoS One 2017;12:e0182124. [PMID: 28832589 DOI: 10.1371/journal.pone.0182124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
72 Flannery L, Liu R, Elmariah S. Dual Antiplatelet Therapy: How Long Is Long Enough? Curr Treat Options Cardiovasc Med 2019;21:17. [PMID: 30929096 DOI: 10.1007/s11936-019-0721-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Woods LT, Forti KM, Shanbhag VC, Camden JM, Weisman GA. P2Y receptors for extracellular nucleotides: Contributions to cancer progression and therapeutic implications. Biochem Pharmacol 2021;187:114406. [PMID: 33412103 DOI: 10.1016/j.bcp.2021.114406] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Fanaroff AC, Clare R, Pieper KS, Mahaffey KW, Melloni C, Green JB, Alexander JH, Jones WS, Harrison RW, Mehta RH, Povsic TJ, Moreira HG, Al-Khatib SM, Roe MT, Kong DF, Mathews R, Tricoci P, Holman RR, Wallentin L, Held C, Califf RM, Alexander KP, Lopes RD. Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. Circulation 2019;139:863-73. [PMID: 30586739 DOI: 10.1161/CIRCULATIONAHA.118.037202] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
75 Chen C, Kan Y, Shi Z, Guo D, Fu W, Li Y, Lv Q, Li X, Si Y. Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis. Front Pharmacol 2020;11:608247. [PMID: 33732144 DOI: 10.3389/fphar.2020.608247] [Reference Citation Analysis]
76 Kalbacher D, Waldeyer C, Blankenberg S, Westermann D. Beyond conventional secondary prevention in coronary artery disease-what to choose in the era of CANTOS, COMPASS, FOURIER, ODYSSEY and PEGASUS-TIMI 54? A review on contemporary literature. Ann Transl Med 2018;6:323. [PMID: 30364059 DOI: 10.21037/atm.2018.08.03] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
77 Park HW, Kang MG, Ahn JH, Bae JS, Tantry US, Gurbel PA, Jeong YH. Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial. J Clin Med 2021;10:2720. [PMID: 34202960 DOI: 10.3390/jcm10122720] [Reference Citation Analysis]
78 Ahmed N, Perek B. Severe complication of early cessation of therapy with ticagrelor after drug-eluting stent implantation. Kardiochir Torakochirurgia Pol 2021;18:119-20. [PMID: 34386056 DOI: 10.5114/kitp.2021.107476] [Reference Citation Analysis]
79 Costa F, Windecker S, Valgimigli M. Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. Drugs 2017;77:1733-54. [PMID: 28853033 DOI: 10.1007/s40265-017-0806-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
80 Howard CE, Nambi V, Jneid H, Khalid U. Extended Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long? J Am Heart Assoc 2019;8:e012639. [PMID: 31576769 DOI: 10.1161/JAHA.119.012639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
81 Kelly CR, Kirtane AJ, Stant J, Stone GW, Minutello RM, Wong SC, Manuzon H, Gerow-Smith R, Kelley N, Rabbani LE. An Updated Protocol for Evaluating Chest Pain and Managing Acute Coronary Syndromes. Crit Pathw Cardiol 2017;16:7-14. [PMID: 28195937 DOI: 10.1097/HPC.0000000000000098] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
82 Melfi R, Ricottini E. Antiplatelet therapy for peripheral artery disease. Cardiovasc Diagn Ther 2018;8:663-77. [PMID: 30498689 DOI: 10.21037/cdt.2018.07.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
83 Furtado RHM, Venkateswaran RV, Nicolau JC, Gurmu Y, Bhatt DL, Storey RF, Steg PG, Magnani G, Goto S, Dellborg M, Kamensky G, Isaza D, Aylward P, Johanson P, Bonaca MP. Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial. J Am Heart Assoc 2020;9:e015785. [PMID: 32410485 DOI: 10.1161/JAHA.119.015785] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
84 Lemesle G, Meurice T, Tricot O, Lamblin N, Bauters C. Association of Diabetic Status and Glycemic Control With Ischemic and Bleeding Outcomes in Patients With Stable Coronary Artery Disease: The 5-Year CORONOR Registry. J Am Heart Assoc 2018;7:e008354. [PMID: 29728374 DOI: 10.1161/JAHA.117.008354] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Li YH, Yeh HI, Hwang JJ. Antithrombotic Treatment for Symptomatic Peripheral Artery Disease. Acta Cardiol Sin 2019;35:557-62. [PMID: 31879506 DOI: 10.6515/ACS.201911_35(6).20190907A] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Li P, Gu Y, Yang Y, Chen L, Liu J, Gao L, Qin Y, Cai Q, Zhao X, Wang Z, Ma L. Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial. Sci Rep 2016;6:31838. [PMID: 27554803 DOI: 10.1038/srep31838] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
87 Mortensen MB, Blaha MJ, Nordestgaard BG. Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention. JAMA Cardiol 2020;5:209-15. [PMID: 31895459 DOI: 10.1001/jamacardio.2019.4759] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
88 Wang Y, Jiang Y, Zhi W, Fu Y, Wang Q, Zhou J, Zheng S, Hao G. Safety and feasibility of low-dose ticagrelor in patients with ST-segment elevation myocardial infarction. Clin Cardiol 2021;44:123-8. [PMID: 33320381 DOI: 10.1002/clc.23517] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Hoogeveen RM, Hanssen NMJ, Brouwer JR, Mosterd A, Tack CJ, Kroon AA, de Borst GJ, Ten Berg J, van Trier T, van Lennep JR, Liem A, Serné E, Visseren FLJ, Cornel JH, Peters RJG, Jukema JW, Stroes ESG; PANORAMA working group. The challenge of choosing in cardiovascular risk management. Neth Heart J 2021. [PMID: 34259995 DOI: 10.1007/s12471-021-01599-y] [Reference Citation Analysis]
90 Kim CH, Han JK, Yang HM, Park KW, Lee HY, Kang HJ, Koo BK, Lee N, Cha TJ, Yang TH, Jeong MH, Yoon MH, Lee SU, Lee SJ, Kim JW, Cho JM, Han KR, Pyun WB, Kim HS. Study protocol for a randomised controlled trial: harmonising optimal strategy for treatment of coronary artery stenosis - coronary intervention with next-generation drug-eluting stent platforms and abbreviated dual antiplatelet therapy (HOST-IDEA) trial. BMJ Open 2017;7:e016617. [PMID: 29025834 DOI: 10.1136/bmjopen-2017-016617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
91 Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, Armstrong PW, White HD, Held C, Aylward PE, Van de Werf F, Harrington RA, Mahaffey KW, Tricoci P. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 2017;38:804-10. [PMID: 28363222 DOI: 10.1093/eurheartj/ehw525] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
92 Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, Yeh RW, D'Agostino RB Sr, Massaro JM, Hsieh WH, Mauri L; DAPT Investigators. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Circulation 2017;135:1720-32. [PMID: 28228427 DOI: 10.1161/CIRCULATIONAHA.116.024835] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
93 Almquist J, Penney M, Pehrsson S, Sandinge AS, Janefeldt A, Maqbool S, Madalli S, Goodman J, Nylander S, Gennemark P. Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (Ticagrelor antidote) by mathematical modeling. CPT Pharmacometrics Syst Pharmacol 2016;5:313-23. [PMID: 27310493 DOI: 10.1002/psp4.12089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
94 Gremmel T, Michelson AD, Frelinger AL III, Bhatt DL. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost 2018;2:439-49. [PMID: 30046748 DOI: 10.1002/rth2.12115] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
95 Mullen L, Meah MN, Elamin A, Aggarwal S, Shahzad A, Shaw M, Hasara J, Rashid M, Fisher M, Ali T, Patel B, Ding WY, Grainger R, Heseltine T, Kirmani BH, Obeidat M, Kasolo Y, Thatchil J, Khand A. Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice. J Am Heart Assoc 2021;10:e019467. [PMID: 33834845 DOI: 10.1161/JAHA.120.019467] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Kim C, Kim BK, Hong SJ, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y. Randomized Comparison of Strut Coverage between Ticagrelor and Clopidogrel in Acute Myocardial Infarction at 3-Month Optical Coherence Tomography. Yonsei Med J 2018;59:624-32. [PMID: 29869460 DOI: 10.3349/ymj.2018.59.5.624] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
97 Bertoluci MC, Moreira RO, Faludi A, Izar MC, Schaan BD, Valerio CM, Bertolami MC, Chacra AP, Malachias MVB, Vencio S, Saraiva JFK, Betti R, Turatti L, Fonseca FAH, Bianco HT, Sulzbach M, Bertolami A, Salles JEN, Hohl A, Trujilho F, Lima EG, Miname MH, Zanella MT, Lamounier R, Sá JR, Amodeo C, Pires AC, Santos RD. Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). Diabetol Metab Syndr 2017;9:53. [PMID: 28725272 DOI: 10.1186/s13098-017-0251-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
98 Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, Cannon CP, Apruzzese PK, D'Agostino RB Sr, Massaro JM, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiol 2017;2:478-87. [PMID: 28297015 DOI: 10.1001/jamacardio.2017.0063] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
99 Usta C, Bedel A. Update on pharmacological treatment of acute coronary syndrome without persistent ST segment elevation myocardial infarction in the elderly. J Geriatr Cardiol 2017;14:457-64. [PMID: 28868074 DOI: 10.11909/j.issn.1671-5411.2017.07.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Gajulapalli RD, Dias S, Pattanshetty DJ, Athappan G. Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a network meta-analysis. Anatol J Cardiol 2017;18:251-60. [PMID: 29076813 DOI: 10.14744/AnatolJCardiol.2017.7672] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
101 Gurbel PA, Myat A, Kubica J, Tantry US. State of the art: Oral antiplatelet therapy. JRSM Cardiovasc Dis 2016;5:2048004016652514. [PMID: 27298725 DOI: 10.1177/2048004016652514] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
102 Patti G, Micieli G, Cimminiello C, Bolognese L. The Role of Clopidogrel in 2020: A Reappraisal. Cardiovasc Ther 2020;2020:8703627. [PMID: 32284734 DOI: 10.1155/2020/8703627] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
103 Petersohn S, Pouwels X, Ramaekers B, Ten Cate-Hoek A, Joore M. Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study. Eur J Prev Cardiol 2020;27:1354-65. [PMID: 32223323 DOI: 10.1177/2047487320913380] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
104 Rapsomaniki E, Thuresson M, Yang E, Blin P, Hunt P, Chung SC, Stogiannis D, Pujades-Rodriguez M, Timmis A, Denaxas SC, Danchin N, Stokes M, Thomas-Delecourt F, Emmas C, Hasvold P, Jennings E, Johansson S, Cohen DJ, Jernberg T, Moore N, Janzon M, Hemingway H. Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. Eur Heart J Qual Care Clin Outcomes 2016;2:172-83. [PMID: 29474617 DOI: 10.1093/ehjqcco/qcw004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
105 Fanaroff AC, Cyr D, Neely ML, Bakal J, White HD, Fox KAA, Armstrong PW, Lopes RD, Ohman EM, Roe MT. Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes. Circ Cardiovasc Qual Outcomes 2018;11:e004755. [PMID: 30562068 DOI: 10.1161/CIRCOUTCOMES.118.004755] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
106 Liu M, Zhuang X, Chen X, Zhang S, Yang D, Zhong X, Xiong Z, Lin Y, Zhou H, Fan Y, Xie P, Huang Y, Wang L, Liao X. Antiplatelet strategy in primary and secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: A perspective from the guideline appraisal. J Diabetes Investig 2021;12:99-108. [PMID: 32543044 DOI: 10.1111/jdi.13324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Parker WAE, Orme RC, Hanson J, Stokes HM, Bridge CM, Shaw PA, Sumaya W, Thorneycroft K, Petrucci G, Porro B, Judge HM, Ajjan RA, Rocca B, Storey RF. Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets 2019;30:148-57. [PMID: 30759035 DOI: 10.1080/09537104.2019.1572880] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
108 Preusch MR, Rusnak J, Staudacher K, Mogler C, Uhlmann L, Sievers P, Bea F, Katus HA, Blessing E, Staudacher I. Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis. Drug Des Devel Ther 2016;10:2691-9. [PMID: 27616880 DOI: 10.2147/DDDT.S105718] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
109 Fanaroff AC, Roe MT. Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. Drug Saf 2016;39:715-27. [PMID: 27028617 DOI: 10.1007/s40264-016-0421-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
110 De Rosa R, Piscione F, Galasso G, De Servi S, Savonitto S. Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes. J Geriatr Cardiol 2019;16:103-13. [PMID: 30923541 DOI: 10.11909/j.issn.1671-5411.2019.02.006] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
111 Gencer B, Li XS, Gurmu Y, Bonaca MP, Morrow DA, Cohen M, Bhatt DL, Steg PG, Storey RF, Johanson P, Wang Z, Hazen SL, Sabatine MS. Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial. J Am Heart Assoc 2020;9:e015331. [PMID: 32366163 DOI: 10.1161/JAHA.119.015331] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
112 Guedeney P, Collet JP. Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines. J Clin Med 2020;9:E3474. [PMID: 33126578 DOI: 10.3390/jcm9113474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
113 Alfredsson J, Roe MT. Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. J Am Heart Assoc 2015;4:e001897. [PMID: 25792126 DOI: 10.1161/JAHA.115.001897] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
114 Godier A, Albaladejo P, On Perioperative Haemostasis Gihp Group TFWG. Management of Bleeding Events Associated with Antiplatelet Therapy: Evidence, Uncertainties and Pitfalls. J Clin Med 2020;9:E2318. [PMID: 32708228 DOI: 10.3390/jcm9072318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
115 Casieri V, Matteucci M, Pasanisi EM, Papa A, Barile L, Fritsche-Danielson R, Lionetti V. Ticagrelor Enhances Release of Anti-Hypoxic Cardiac Progenitor Cell-Derived Exosomes Through Increasing Cell Proliferation In Vitro. Sci Rep 2020;10:2494. [PMID: 32051439 DOI: 10.1038/s41598-020-59225-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
116 Resor CD, Nathan A, Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Gabriel Steg P, Hsieh WH, Mauri L; Dual Antiplatelet Therapy Study Investigators. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. Circulation 2016;134:989-98. [PMID: 27576774 DOI: 10.1161/CIRCULATIONAHA.116.024531] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
117 Arnold N, Lechner K, Waldeyer C, Shapiro MD, Koenig W. Inflammation and Cardiovascular Disease: The Future. Eur Cardiol 2021;16:e20. [PMID: 34093741 DOI: 10.15420/ecr.2020.50] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
118 Kubica J, Adamski P, Niezgoda P, Alexopoulos D, Badarienė J, Budaj A, Buszko K, Dudek D, Fabiszak T, Gąsior M, Gil R, Gorog DA, Grajek S, Gurbel PA, Gruchała M, Jaguszewski MJ, James S, Jeong YH, Jilma B, Kasprzak JD, Kleinrok A, Kubica A, Kuliczkowski W, Legutko J, Lesiak M, Siller-Matula JM, Nadolny K, Pstrągowski K, Di Somma S, Specchia G, Stępińska J, Tantry US, Tycińska A, Verdoia M, Wojakowski W, Navarese EP. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiol J 2020;27:661-76. [PMID: 33073857 DOI: 10.5603/CJ.a2020.0132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
119 Gradolí J, Vidal V, Brady AJ, Facila L. Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS Study. Eur Cardiol 2018;13:115-8. [PMID: 30697356 DOI: 10.15420/ecr.2018.12.2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
120 Koushki K, Shahbaz SK, Mashayekhi K, Sadeghi M, Zayeri ZD, Taba MY, Banach M, Al-Rasadi K, Johnston TP, Sahebkar A. Anti-inflammatory Action of Statins in Cardiovascular Disease: the Role of Inflammasome and Toll-Like Receptor Pathways. Clin Rev Allergy Immunol 2021;60:175-99. [PMID: 32378144 DOI: 10.1007/s12016-020-08791-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 22.0] [Reference Citation Analysis]
121 Song JW, Soh S, Shim JK. Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications. Korean J Anesthesiol 2017;70:13-21. [PMID: 28184261 DOI: 10.4097/kjae.2017.70.1.13] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
122 Verdoia M, Suryapranata H, Damen S, Camaro C, Benit E, Barbieri L, Rasoul S, Liew HB, Polad J, Ahmad WAW, Zambahari R, Lalmand J, van der Schaaf RJ, Koh TH, Timmermans P Sr, Dilling-Boer D, Veenstra LF, Van't Hof AWJ, Lee SWL, Roolvink V, Ligtenberg E, Postma S, Kolkman EJJ, Brouwer MA, Kedhi E, De Luca G. Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial. J Thromb Thrombolysis 2021. [PMID: 33847862 DOI: 10.1007/s11239-021-02439-x] [Reference Citation Analysis]
123 Santucci A, Riccini C, Cavallini C. Treatment of stable ischaemic heart disease: the old and the new. Eur Heart J Suppl 2020;22:E54-9. [PMID: 32523440 DOI: 10.1093/eurheartj/suaa060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
124 Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka KI, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 Investigators. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA 2019;321:2414-27. [PMID: 31237644 DOI: 10.1001/jama.2019.8145] [Cited by in Crossref: 279] [Cited by in F6Publishing: 179] [Article Influence: 139.5] [Reference Citation Analysis]
125 Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, Bhatt DL, Oude Ophuis T, Budaj A, Hamm C, Spinar J, Kiss RG, Lopez-Sendon J, Kamensky G, Van de Werf F, Ardissino D, Kontny F, Montalescot G, Johanson P, Bengtsson O, Himmelmann A, Braunwald E, Sabatine MS. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Eur Heart J Cardiovasc Pharmacother 2019;5:200-6. [PMID: 31218354 DOI: 10.1093/ehjcvp/pvz020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
126 Fanaroff AC, Kaltenbach LA, Peterson ED, Akhter MW, Effron MB, Henry TD, Wang TY. Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study. J Am Heart Assoc 2018;7:e007982. [PMID: 29437596 DOI: 10.1161/JAHA.117.007982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
127 Ajjan RA, Kietsiriroje N, Badimon L, Vilahur G, Gorog DA, Angiolillo DJ, Russell DA, Rocca B, Storey RF. Antithrombotic therapy in diabetes: which, when, and for how long? Eur Heart J 2021;42:2235-59. [PMID: 33764414 DOI: 10.1093/eurheartj/ehab128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Blin P, Dureau-Pournin C, Lassalle R, Jové J, Thomas-Delecourt F, Droz-Perroteau C, Danchin N, Moore N. Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database. Br J Clin Pharmacol 2017;83:2056-65. [PMID: 28345154 DOI: 10.1111/bcp.13291] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
129 Fanaroff AC, Hasselblad V, Roe MT, Bhatt DL, James SK, Steg PG, Gibson CM, Ohman EM. Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. Int J Cardiol 2017;241:87-96. [PMID: 28320608 DOI: 10.1016/j.ijcard.2017.03.046] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
130 Lebas H, Yahiaoui K, Martos R, Boulaftali Y. Platelets Are at the Nexus of Vascular Diseases. Front Cardiovasc Med 2019;6:132. [PMID: 31572732 DOI: 10.3389/fcvm.2019.00132] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
131 Magnani G, Ardissino D, Im K, Budaj A, Storey RF, Steg PG, Bhatt DL, Cohen M, Oude Ophius T, Goudev A, Parkhomenko A, Kamensky G, Angiolillo DJ, López-Sendón J, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. J Am Heart Assoc 2021;10:e017008. [PMID: 33559485 DOI: 10.1161/JAHA.120.017008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Smolensky Koganov E, Michelson AD, Yanachkov IB, Yanachkova MI, Wright GE, Przyklenk K, Frelinger AL 3rd. GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep 2018;8:14529. [PMID: 30266987 DOI: 10.1038/s41598-018-32797-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
133 Kosobucka A, Michalski P, Pietrzykowski Ł, Kasprzak M, Obońska K, Fabiszak T, Felsmann M, Kubica A. Adherence to treatment assessed with the Adherence in Chronic Diseases Scale in patients after myocardial infarction. Patient Prefer Adherence 2018;12:333-40. [PMID: 29551891 DOI: 10.2147/PPA.S150435] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
134 Brunetti ND, De Gennaro L, Di Biase M, Caldarola P. Prolonged double antiplatelet therapy vs association of antiplatelet and low dose of anticoagulant therapy: PEGASUS or COMPASS? Int J Cardiol Heart Vasc 2019;24:100401. [PMID: 31763434 DOI: 10.1016/j.ijcha.2019.100401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
135 Yun JE, Kim YJ, Park JJ, Kim S, Park K, Cho MS, Nam GB, Park DW. Safety and Effectiveness of Contemporary P2Y12 Inhibitors in an East Asian Population With Acute Coronary Syndrome: A Nationwide Population-Based Cohort Study. J Am Heart Assoc 2019;8:e012078. [PMID: 31310570 DOI: 10.1161/JAHA.119.012078] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
136 Alomari M, Bratton H, Musmar A, Al Momani LA, Young M. Ticagrelor-induced Diarrhea in a Patient with Acute Coronary Syndrome Requiring Percutaneous Coronary Artery Intervention. Cureus 2019;11:e3874. [PMID: 30899625 DOI: 10.7759/cureus.3874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 Thiele H, Jobs A. [ESC guidelines 2020: acute coronary syndrome without persistent ST-segment elevation : What is new?]. Herz 2021;46:3-13. [PMID: 33236199 DOI: 10.1007/s00059-020-05002-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, Valgimigli M, Windecker S, James SK, Buccheri S, Ten Berg JM, Henriques JPS, Voskuil M, Kikkert WJ. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. Eur Heart J 2021;42:1038-46. [PMID: 33515031 DOI: 10.1093/eurheartj/ehaa1097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Ribeiro DR, Cambruzzi E, Schmidt MM, Quadros AS. Thrombosis in ST-elevation myocardial infarction: Insights from thrombi retrieved by aspiration thrombectomy. World J Cardiol 2016;8:362-7. [PMID: 27354893 DOI: 10.4330/wjc.v8.i6.362] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
140 Marston NA, Bonaca MP, Jarolim P, Goodrich EL, Bhatt DL, Steg PG, Cohen M, Storey RF, Johanson P, Wiviott SD, Braunwald E, Sabatine MS, Morrow DA. Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiol 2020;5:1255-62. [PMID: 32756916 DOI: 10.1001/jamacardio.2020.2981] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
141 Henriksson R, Björklund F, Mooe T. The introduction of ticagrelor is associated with lower rates of recurrent ischemic stroke after myocardial infarction. PLoS One 2019;14:e0216404. [PMID: 31059535 DOI: 10.1371/journal.pone.0216404] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Ahn YH, Lee JY, Park HD, Kim TH, Park MC, Choi G, Kim S. Identification of a New Morpholine Scaffold as a P2Y12 Receptor Antagonist. Molecules 2016;21:E1114. [PMID: 27563870 DOI: 10.3390/molecules21091114] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
143 Ribera A, Ferreira-Gonzalez I, Marsal JR, Oristrell G, Faixedas MT, Rosas A, Tizón-Marcos H, Rojas S, Labata C, Cardenas M, Homs S, Tomas-Querol C, Garcia-Picart J, Gomez-Hospital JA, Pijoan JI, Masotti M, Mauri J, Garcia Dorado D; VESA Study and Codi IAM Investigators. Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-segment elevation acute coronary syndrome: a population-based cohort study in Catalonia (Spain). BMJ Open 2019;9:e028114. [PMID: 31340964 DOI: 10.1136/bmjopen-2018-028114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
144 Sharma AN, Deyell JS, Sharma SN, Barseghian A. Role of and Recent Evidence for Antiplatelet Therapy in Prevention of Cardiovascular Disease in Diabetes. Curr Cardiol Rep 2019;21:78. [PMID: 31254105 DOI: 10.1007/s11886-019-1168-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
145 Puymirat E, Bonaca M, Fumery M, Tea V, Aissaoui N, Lemesles G, Bonello L, Ducrocq G, Cayla G, Ferrières J, Schiele F, Simon T, Danchin N; FAST-MI investigators. Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non-ST Elevation Myocardial Infarction registries. Clin Cardiol 2019;42:227-34. [PMID: 30536449 DOI: 10.1002/clc.23131] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
146 Kikkert WJ, Damman P. Optimal duration of dual antiplatelet therapy for coronary artery disease. Neth Heart J 2018;26:321-33. [PMID: 29713989 DOI: 10.1007/s12471-018-1113-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
147 Sterpetti AV. Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications. Curr Atheroscler Rep 2020;22:75. [PMID: 33025148 DOI: 10.1007/s11883-020-00891-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
148 Sharma R, Kumar P, Prashanth SP, Belagali Y. Dual Antiplatelet Therapy in Coronary Artery Disease. Cardiol Ther 2020;9:349-61. [PMID: 32804330 DOI: 10.1007/s40119-020-00197-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Glazier JJ, Ramos-Parra B, Kaki A. Therapeutic Options for Left Main, Left Main Equivalent, and Three-Vessel Disease. Int J Angiol 2021;30:76-82. [PMID: 34025098 DOI: 10.1055/s-0041-1723977] [Reference Citation Analysis]
150 McClure GR, Kaplovitch E, Narula S, Bhagirath VC, Anand SS. Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios. Curr Cardiol Rep 2019;21:115. [PMID: 31471666 DOI: 10.1007/s11886-019-1198-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
151 Abtan J, Bhatt DL, Elbez Y, Sorbets E, Eagle K, Ikeda Y, Wu D, Hanson ME, Hannachi H, Singhal PK, Steg PG, Ducrocq G; REACH Registry Investigators. Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry. Clin Cardiol 2016;39:670-7. [PMID: 27588731 DOI: 10.1002/clc.22583] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 5.6] [Reference Citation Analysis]
152 Gillette M, Morneau K, Hoang V, Virani S, Jneid H. Antiplatelet Management for Coronary Heart Disease: Advances and Challenges. Curr Atheroscler Rep 2016;18:35. [PMID: 27139709 DOI: 10.1007/s11883-016-0581-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
153 Esmonde S, Sharma D, Peace A. Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare. Cardiovasc Diagn Ther 2018;8:647-62. [PMID: 30498688 DOI: 10.21037/cdt.2018.06.09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
154 Capodanno D, Bhatt DL, Eikelboom JW, Fox KAA, Geisler T, Michael Gibson C, Gonzalez-Juanatey JR, James S, Lopes RD, Mehran R, Montalescot G, Patel M, Steg PG, Storey RF, Vranckx P, Weitz JI, Welsh R, Zeymer U, Angiolillo DJ. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Rev Cardiol 2020;17:242-57. [PMID: 31953535 DOI: 10.1038/s41569-019-0314-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 37.0] [Reference Citation Analysis]
155 Berger JS. Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome. Am J Cardiovasc Drugs 2018;18:457-72. [PMID: 29987548 DOI: 10.1007/s40256-018-0291-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
156 Dhindsa DS, Sandesara PB, Shapiro MD, Wong ND. The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Front Cardiovasc Med 2020;7:88. [PMID: 32478100 DOI: 10.3389/fcvm.2020.00088] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
157 Moss AJ, Dweck MR, Doris MK, Andrews JPM, Bing R, Forsythe RO, Cartlidge TR, Pawade TA, Daghem M, Raftis JB, Williams MC, van Beek EJR, Forsyth L, Lewis SC, Lee RJ, Shah ASV, Mills NL, Newby DE, Adamson PD. Ticagrelor to Reduce Myocardial Injury in Patients With High-Risk Coronary Artery Plaque. JACC Cardiovasc Imaging 2020;13:1549-60. [PMID: 31422134 DOI: 10.1016/j.jcmg.2019.05.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
158 Zheng B, Huo Y, Lee SW, Sawhney JPS, Kim HS, Krittayaphong R, Pocock SJ, Nhan VT, Alonso Garcia A, Chin CT, Jiang J, Jan S, Vega AM, Hayashi N, Ong TK. Long-term antithrombotic management patterns in Asian patients with acute coronary syndrome: 2-year observations from the EPICOR Asia study. Clin Cardiol 2020;43:999-1008. [PMID: 32618009 DOI: 10.1002/clc.23400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
159 Wilson SJ, Newby DE, Dawson D, Irving J, Berry C. Duration of dual antiplatelet therapy in acute coronary syndrome. Heart 2017;103:573-80. [PMID: 28249994 DOI: 10.1136/heartjnl-2016-309871] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
160 Kubisa MJ, Jezewski MP, Gasecka A, Siller-Matula JM, Postuła M. Ticagrelor - toward more efficient platelet inhibition and beyond. Ther Clin Risk Manag 2018;14:129-40. [PMID: 29398917 DOI: 10.2147/TCRM.S152369] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 10.3] [Reference Citation Analysis]
161 Iqbal J, Serruys PW. Optimal medical therapy is vital for patients with coronary artery disease and acute coronary syndromes regardless of revascularization strategy. Ann Transl Med 2017;5:140. [PMID: 28462220 DOI: 10.21037/atm.2017.02.15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
162 Liebetrau C, Hamm CW. [Management of acute coronary syndrome without ST-segment elevation]. Herz 2017;42:211-28. [PMID: 28233037 DOI: 10.1007/s00059-017-4541-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
163 Bueno H, Pocock S, Danchin N, Annemans L, Gregson J, Medina J, Van de Werf F. International patterns of dual antiplatelet therapy duration after acute coronary syndromes. Heart 2017;103:132-8. [PMID: 27504002 DOI: 10.1136/heartjnl-2016-309509] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 6.8] [Reference Citation Analysis]
164 Walker J, Cattaneo M, Badimon L, Agnelli G, Chan AT, Lanas A, Rocca B, Rothwell P, Patrignani P, Langley R, Vilahur G, Cosentino F. Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. Ecancermedicalscience 2020;14:998. [PMID: 32153653 DOI: 10.3332/ecancer.2020.998] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
165 Mo F, Li J, Yan Y, Wu W, Lai S. Effect and safety of antithrombotic therapies for secondary prevention after acute coronary syndrome: a network meta-analysis. Drug Des Devel Ther 2018;12:3583-94. [PMID: 30498334 DOI: 10.2147/DDDT.S166544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
166 Timmis A, Rapsomaniki E, Chung SC, Pujades-Rodriguez M, Moayyeri A, Stogiannis D, Shah AD, Pasea L, Denaxas S, Emmas C, Hemingway H. Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations. BMJ 2016;353:i3163. [PMID: 27334486 DOI: 10.1136/bmj.i3163] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
167 Chaitman BR, Alexander KP, Cyr DD, Berger JS, Reynolds HR, Bangalore S, Boden WE, Lopes RD, Demkow M, Piero Perna G, Riezebos RK, McFalls EO, Banerjee S, Bagai A, Gosselin G, O'Brien SM, Rockhold FW, Waters DD, Thygesen KA, Stone GW, White HD, Maron DJ, Hochman JS; ISCHEMIA Research Group. Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. Circulation 2021;143:790-804. [PMID: 33267610 DOI: 10.1161/CIRCULATIONAHA.120.047987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 11.0] [Reference Citation Analysis]
168 Fierro JJ, Cave B, Khouzam RN. P2Y12 inhibitors: do they increase cancer risk? Ann Transl Med 2019;7:409. [PMID: 31660308 DOI: 10.21037/atm.2019.07.90] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
169 Teng R, Hammarberg M, Carlson GF, Bokelund-Singh S, Ruderfelt T, Blychert E. Pharmacokinetic Profiles of Ticagrelor Orodispersible Tablets in Healthy Western and Japanese Subjects. Clin Drug Investig 2017;37:1035-45. [PMID: 28856602 DOI: 10.1007/s40261-017-0554-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
170 Singh P, Harper Y, Oliphant CS, Morsy M, Skelton M, Askari R, Khouzam RN. Peripheral interventions and antiplatelet therapy: Role in current practice. World J Cardiol 2017;9:583-93. [PMID: 28824788 DOI: 10.4330/wjc.v9.i7.583] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
171 Ramadan R, Boden WE, Kinlay S. Management of Left Main Coronary Artery Disease. J Am Heart Assoc. 2018;7. [PMID: 29605817 DOI: 10.1161/jaha.117.008151] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 9.3] [Reference Citation Analysis]
172 McCune C, McKavanagh P, Menown IB. A Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients. Cardiol Ther 2015;4:95-116. [PMID: 26396083 DOI: 10.1007/s40119-015-0047-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
173 Aungraheeta R, Conibear A, Butler M, Kelly E, Nylander S, Mumford A, Mundell SJ. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood 2016;128:2717-28. [PMID: 27694321 DOI: 10.1182/blood-2016-03-707844] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 9.6] [Reference Citation Analysis]
174 Teng R. Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clin Pharmacokinet 2015;54:1125-38. [PMID: 26063049 DOI: 10.1007/s40262-015-0290-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 37] [Article Influence: 11.6] [Reference Citation Analysis]
175 Sorbets E, Steg PG. Direct-acting Anticoagulants in Chronic Coronary Syndromes. Eur Cardiol 2020;15:1-7. [PMID: 32180831 DOI: 10.15420/ecr.2018.24.2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Nylander S, Schulz R. Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines. Br J Pharmacol 2016;173:1163-78. [PMID: 26758983 DOI: 10.1111/bph.13429] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 11.8] [Reference Citation Analysis]
177 Lohaus R, Michel J, Mayer K, Lahmann AL, Byrne RA, Wolk A, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, Tölg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Wöhrle J, Kufner S, Morath T, Ibrahim T, Bernlochner I, Fischer M, Schunkert H, Laugwitz KL, Mehilli J, Kastrati A, Schulz-Schüpke S. Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. Sci Rep 2016;6:33054. [PMID: 27624287 DOI: 10.1038/srep33054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
178 Bhatt DL, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, Andersson M, Himmelmann A, Ridderstråle W, Held C, Steg PG; THEMIS Steering Committee. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clin Cardiol 2019;42:498-505. [PMID: 30788847 DOI: 10.1002/clc.23164] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
179 Gulizia MM, Colivicchi F, Abrignani MG, Ambrosetti M, Aspromonte N, Barile G, Caporale R, Casolo G, Chiuini E, Di Lenarda A, Faggiano P, Gabrielli D, Geraci G, La Manna AG, Maggioni AP, Marchese A, Massari FM, Mureddu GF, Musumeci G, Nardi F, Panno AV, Pedretti RFE, Piredda M, Pusineri E, Riccio C, Rossini R, di Uccio FS, Urbinati S, Varbella F, Zito GB, De Luca L; ESC Scientific Document Group ., Faculty for approval of the Consensus Document . Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. Eur Heart J Suppl 2018;20:F1-F74. [PMID: 29867293 DOI: 10.1093/eurheartj/suy019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 5.7] [Reference Citation Analysis]
180 Kim HK, Kim HB, Lee JM, Kim SS, Bae IH, Park DS, Park JK, Shim JW, Na JY, Lee MY, Kim JS, Sim DS, Hong YJ, Nam CW, Doh JH, Park J, Koo BK, Kim SU, Lim KS, Jeong MH. Influence of Local Myocardial Infarction on Endothelial Function, Neointimal Progression, and Inflammation in Target and Non-Target Vascular Territories in a Porcine Model of Acute Myocardial Infarction. J Korean Med Sci 2019;34:e145. [PMID: 31099195 DOI: 10.3346/jkms.2019.34.e145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Pasalic L, Wing-Lun E, Lau JK, Campbell H, Pennings GJ, Lau E, Connor D, Liang HP, Muller D, Kritharides L, Hogg PJ, Chen VM. Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response. J Thromb Haemost 2018;16:1198-210. [PMID: 29569428 DOI: 10.1111/jth.14008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
182 Halim H, Pinkaew D, Chunhacha P, Sinthujaroen P, Thiagarajan P, Fujise K. Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel. PLoS One 2019;14:e0218934. [PMID: 31242230 DOI: 10.1371/journal.pone.0218934] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
183 Kim HK, Ahn Y, Chang K, Jeong YH, Hahn JY, Choo EH, Kim MC, Kim HS, Kim W, Cho MC, Jang Y, Kim CJ, Jeong MH, Chae SC; Task Force on Expert Consensus Document of the Korean Society of Myocardial Infarction (KSMI). 2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction. Korean Circ J 2020;50:845-66. [PMID: 32969206 DOI: 10.4070/kcj.2020.0196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
184 De Luca L, Bellettini E, Di Maio D, Natale E, Putini RL, Anticoli S, Colivicchi F, Calabrò P, Musumeci F, Gabrielli D. Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events. J Clin Med 2021;10:1721. [PMID: 33923493 DOI: 10.3390/jcm10081721] [Reference Citation Analysis]
185 Kim L, Choe JC, Ahn JH, Lee HW, Oh JH, Choi JH, Lee HC, Cha KS, Hong TJ, Jeong YH, Park JS. Temporal Trends of Bleeding Episodes during Half- vs. Standard-Dose Ticagrelor in Acute Coronary Syndrome Patients with Low Platelet Reactivity: A Randomized BLEEDING-ACS Trial. J Clin Med 2021;10:1159. [PMID: 33802015 DOI: 10.3390/jcm10061159] [Reference Citation Analysis]
186 Verdoia M, Camaro C, Kedhi E, Marcolongo M, Suryapranata H, De Luca G. Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues. Cardiovasc Ther 2020;2020:6495036. [PMID: 32328172 DOI: 10.1155/2020/6495036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
187 Han YL. De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review. Chin Med J (Engl) 2019;132:197-210. [PMID: 30614864 DOI: 10.1097/CM9.0000000000000047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
188 Li S, Sun X, Wu H, Yu P, Wang X, Jiang Z, Gao E, Chen J, Li, Qiu C, Song B, Chen K, He K, Yang D, Yang Y. TRPA1 Promotes Cardiac Myofibroblast Transdifferentiation after Myocardial Infarction Injury via the Calcineurin-NFAT-DYRK1A Signaling Pathway. Oxid Med Cell Longev 2019;2019:6408352. [PMID: 31217840 DOI: 10.1155/2019/6408352] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
189 Su-Yin DT. Using Pharmacogenetic Testing or Platelet Reactivity Testing to Tailor Antiplatelet Therapy: Are Asians different from Caucasians? Eur Cardiol 2018;13:112-4. [PMID: 30697355 DOI: 10.15420/ecr.2018.13.2.EO2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
190 Sandinge AS, Janefeldt A, Pehrsson S, Nylander S. Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452. PLoS One 2018;13:e0201202. [PMID: 30048515 DOI: 10.1371/journal.pone.0201202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
191 Sharma PK, Chhatriwalla AK, Cohen DJ, Jang JS, Baweja P, Gosch K, Jones P, Bach RG, Arnold SV, Spertus JA. Predicting long-term bleeding after percutaneous coronary intervention. Catheter Cardiovasc Interv 2017;89:199-206. [PMID: 27037854 DOI: 10.1002/ccd.26529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
192 Abola MTB, Golledge J, Miyata T, Rha SW, Yan BP, Dy TC, Ganzon MSV, Handa PK, Harris S, Zhisheng J, Pinjala R, Robless PA, Yokoi H, Alajar EB, Bermudez-Delos Santos AA, Llanes EJB, Obrado-Nabablit GM, Pestaño NS, Punzalan FE, Tumanan-Mendoza B. Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee. J Atheroscler Thromb 2020;27:809-907. [PMID: 32624554 DOI: 10.5551/jat.53660] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
193 Thiele H, Desch S, de Waha S. [Acute myocardial infarction in patients with ST-segment elevation myocardial infarction : ESC guidelines 2017]. Herz 2017;42:728-38. [PMID: 29119223 DOI: 10.1007/s00059-017-4641-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
194 Spinthakis N, Farag M, Rocca B, Gorog DA. More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. J Am Heart Assoc 2018;7:e007754. [PMID: 29374045 DOI: 10.1161/JAHA.117.007754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
195 Marcano AL, Ferreiro JL. Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor. Curr Atheroscler Rep 2016;18:66. [PMID: 27714642 DOI: 10.1007/s11883-016-0617-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
196 Turgeon RD, Koshman SL, Youngson E, Har B, Wilton SB, James MT, Graham MM. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA Intern Med 2020;180:420-8. [PMID: 31930361 DOI: 10.1001/jamainternmed.2019.6447] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 22.0] [Reference Citation Analysis]
197 Gaudino M, Angiolillo DJ, Di Franco A, Capodanno D, Bakaeen F, Farkouh ME, Fremes SE, Holmes D, Girardi LN, Nakamura S, Head SJ, Park SJ, Mack M, Serruys PW, Ruel M, Stone GW, Tam DY, Vallely M, Taggart DP. Stroke After Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention: Incidence, Pathogenesis, and Outcomes. J Am Heart Assoc 2019;8:e013032. [PMID: 31242821 DOI: 10.1161/JAHA.119.013032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 7.5] [Reference Citation Analysis]
198 Castini D, Persampieri S, Sabatelli L, Erba M, Ferrante G, Valli F, Centola M, Carugo S. Utility of the HAS-BLED score for risk stratification of patients with acute coronary syndrome. Heart Vessels 2019;34:1621-30. [PMID: 30969359 DOI: 10.1007/s00380-019-01405-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
199 Pasea L, Chung SC, Pujades-Rodriguez M, Shah AD, Alvarez-Madrazo S, Allan V, Teo JT, Bean D, Sofat R, Dobson R, Banerjee A, Patel RS, Timmis A, Denaxas S, Hemingway H. Bleeding in cardiac patients prescribed antithrombotic drugs: electronic health record phenotyping algorithms, incidence, trends and prognosis. BMC Med 2019;17:206. [PMID: 31744503 DOI: 10.1186/s12916-019-1438-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
200 Gremmel T, Yanachkov IB, Yanachkova MI, Wright GE, Wider J, Undyala VV, Michelson AD, Frelinger AL 3rd, Przyklenk K. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arterioscler Thromb Vasc Biol 2016;36:501-9. [PMID: 26743169 DOI: 10.1161/ATVBAHA.115.306885] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
201 Bauersachs R, Wu O, Briere JB, Bowrin K, Borkowska K, Jakubowska A, Taieb V, Toumi M, Huelsebeck M. Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials. Cardiovasc Ther 2020;2020:3057168. [PMID: 32695228 DOI: 10.1155/2020/3057168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
202 Fanari Z, Malodiya A, Weiss SA, Hammami S, Kolm P, Weintraub WS. Long-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: Meta-analysis of randomized controlled trials. Cardiovasc Revasc Med 2017;18:10-5. [PMID: 27477306 DOI: 10.1016/j.carrev.2016.07.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
203 Halbach M, Baldus S. [Platelet inhibition in patients with coronary, cerebral and peripheral macroangiopathy : What, when and how long?]. Internist (Berl) 2018;59:288-303. [PMID: 29340741 DOI: 10.1007/s00108-017-0362-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
204 Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A, Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Sangiorgi D, Biondi-Zoccai G, Généreux P, Angelini GD, Pufulete M, White J, Bhatt DL, Stone GW. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J 2017;38:1034-43. [PMID: 28110296 DOI: 10.1093/eurheartj/ehw627] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
205 Zhang Y, Shi XJ, Peng WX, Han JL, Lin BD, Zhang R, Zhang YN, Yan JL, Wei JJ, Wang YF, Chen SW, Nan N, Fang ZW, Zeng Y, Lin Y. Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China. Front Pharmacol 2020;11:582929. [PMID: 33551797 DOI: 10.3389/fphar.2020.582929] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
206 Warden BA, Purnell JQ, Duell PB, Craigan C, Osborn D, Cabot E, Fazio S. Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice. Am J Prev Cardiol 2021;5:100144. [PMID: 34327487 DOI: 10.1016/j.ajpc.2020.100144] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
207 Tan JWC, Chew DP, Brieger D, Eikelboom J, Montalescot G, Ako J, Kim BK, Quek DK, Aitken SJ, Chow CK, Chour S, Tse HF, Kaul U, Firdaus I, Kubo T, Liew BW, Chong TT, Sin KY, Yeh HI, Buddhari W, Chunhamaneewat N, Hasan F, Fox KA, Nguyen QN, Lo ST. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome. Eur Cardiol 2021;16:e26. [PMID: 34249148 DOI: 10.15420/ecr.2020.45] [Reference Citation Analysis]
208 Mearns BM. Antiplatelet therapy. Long-term ticagrelor use in patients with history of MI. Nat Rev Cardiol 2015;12:260. [PMID: 25824506 DOI: 10.1038/nrcardio.2015.49] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
209 Aquila G, Vieceli Dalla Sega F, Marracino L, Pavasini R, Cardelli LS, Piredda A, Scoccia A, Martino V, Fortini F, Bononi I, Martini F, Manfrini M, Pannuti A, Ferrari R, Rizzo P, Campo G. Ticagrelor Increases SIRT1 and HES1 mRNA Levels in Peripheral Blood Cells from Patients with Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease. Int J Mol Sci 2020;21:E1576. [PMID: 32106619 DOI: 10.3390/ijms21051576] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
210 Wen S, Wang F, Ji Z, Pan Y, Jian M, Bi Y, Zhou G, Luo L, Chen T, Li L, Ding Z, Abi ME, Liu A, Bao F. Salp15, a Multifunctional Protein From Tick Saliva With Potential Pharmaceutical Effects. Front Immunol 2019;10:3067. [PMID: 31998324 DOI: 10.3389/fimmu.2019.03067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
211 Fei Y, Lam CK, Cheung BMY. Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta-analysis. Sci Rep 2020;10:16794. [PMID: 33033323 DOI: 10.1038/s41598-020-73871-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
212 Li H, Guo J, Carlson GF, Teng R. Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. Br J Clin Pharmacol 2016;82:352-61. [PMID: 27038001 DOI: 10.1111/bcp.12950] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
213 Zeitouni M, Clare RM, Chiswell K, Abdulrahim J, Shah N, Pagidipati NP, Shah SH, Roe MT, Patel MR, Jones WS. Risk Factor Burden and Long-Term Prognosis of Patients With Premature Coronary Artery Disease. J Am Heart Assoc 2020;9:e017712. [PMID: 33287625 DOI: 10.1161/JAHA.120.017712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
214 Åstrand M, Amilon C, Röshammar D, Himmelmann A, Angiolillo DJ, Storey RF, Gurbel PA, Bonaca MP, Hamrén B. Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. Br J Clin Pharmacol 2019;85:413-21. [PMID: 30414387 DOI: 10.1111/bcp.13812] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
215 Rauch B. Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia. Eur J Prev Cardiol 2020;27:1351-3. [PMID: 32301349 DOI: 10.1177/2047487320920754] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]